Martins Eduardo Bruno 4
4 · Sagimet Biosciences Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Sagimet (SGMT) CMO Martins Bruno Receives Equity Awards
What Happened
Martins Eduardo Bruno, Chief Medical Officer of Sagimet Biosciences, was granted two equity awards on February 19, 2026: 44,000 restricted stock units (RSUs) and 88,000 derivative awards (option-based rights). Both grants show an acquisition price of $0.00 — these are compensation awards, not open-market purchases or sales.
Key Details
- Transaction date: February 19, 2026; Form 4 filed February 20, 2026 (timely filing).
- Awards: 44,000 RSUs (F1) and 88,000 derivative awards/options (A, derivative). No cash paid ($0.00 per share).
- Vesting: RSUs vest in four equal annual installments beginning Feb 19, 2026 (F1). The derivative awards vest and become exercisable in 48 equal monthly installments beginning Feb 19, 2026 (F2).
- Shares owned after transaction: Not disclosed in this filing.
- No indication of a 10b5-1 plan, tax withholding sale, or late filing in this record.
Context
RSUs convert to actual shares upon vesting and settlement; the 88,000 derivative awards are option-like and will only become exercisable over time as they vest. Because these are compensation grants rather than purchases or sales, they reflect standard equity-based compensation rather than an immediate trading decision.
Insider Transaction Report
- Award
Series A Common Stock
[F1]2026-02-19+44,000→ 147,296 total - Award
Stock Option (Right to Buy)
[F2]2026-02-19+88,000→ 88,000 totalExercise: $5.38Exp: 2036-02-18→ Series A Common Stock (88,000 underlying)
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.
- [F2]The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.